Skip to main content
. 2020 Jan 14;4(1):191–202. doi: 10.1182/bloodadvances.2019000836

Table 4.

Association of transplant variables with the recovery of T-cell subsets and function

Variable CD4+ T cells CD4+CD45RA+ T cells CD8+ T cells PHA
Slope (95% CI) P Slope (95% CI) P Slope (95% CI) P Slope (95% CI) P
Age (10 y) −0.09 (−0.20, 0.01) .087 −0.05 (−0.22, 0.12) .539 0.01 (−0.15, 0.16) .924 −0.08 (−0.21, 0.04) .205
8-allele HLA-match* .200 .545 .105 .565
 <5/8 reference reference reference reference
 ≥5/8 0.19 (−0.10, 0.47) 0.14 (−0.30, 0.58) −0.33 (−0.73, 0.07) 0.09 (−0.22, 0.41)
Infused viable CD34+ cell dose* .646 .333 .245 .574
 <1.18 × 105/kg reference reference reference reference
 ≥1.18 × 105/kg −0.06 (−0.32, 0.20) −0.20 (−0.60, 0.20) 0.22 (−0.15, 0.58) 0.08 (−0.21, 0.37)
Infused viable CD3+ cell dose* .045 .020 .893 .065
 <3.34 × 106/kg reference reference reference reference
 ≥3.34 × 106/kg 0.26 (0.01, 0.52) 0.47 (0.08, 0.87) 0.03 (−0.34, 0.39) 0.27 (−0.01, 0.56)
CMV reactivation by day 60 .005 .171 <.001 <.001
 No CMV reactivation reference Reference reference reference
 CMV reactivation −0.39 (−0.66, −0.13) −0.31 (−0.75, 0.13) 1.15 (0.77, 1.52) −0.58 (−0.86, −0.29)
Day 100 aGVHD grade .651 .386 .630 .435
 0-I reference reference reference reference
 II −0.16 (−0.52, 0.20) −0.05 (−0.62, 0.51) 0.29 (−0.32, 0.90) −0.20 (−0.61, 0.21)
 III-IV −0.19 (−0.65, 0.27) 0.37 (0.36, 1.10) 0.30 (−0.48, 1.07) −0.33 (−0.83, 0.17)
*

Engrafting CB unit.

There was no association with the variables of recipient sex, diagnosis (acute leukemia vs MDS/MPD vs lymphoma), or the addition of haploidentical CD34+ cells (data not shown). P values significant at the .01 level are indicated in bold.